Mobile

Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial ...

Update Il y a 4 ans
Reference: EUCTR2008-003610-94

Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

to evaluate the long-term safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in treatment of naive patients and patients pretreated with an Endothelin Receptor Antagonist or a Prostacyclinanalogue with symptomatic Pulmonary Arterial Hypertension (PAH)

Inclusion criteria

  • Pulmonary Arterial Hypertension (PAH)

Links